Stockscreener 앱 받기
1.25
0.00%
0.00
전일 마감가:
$1.25
열려 있는:
$1.24
하루 거래량:
58,465
Relative Volume:
0.31
시가총액:
$18.51M
수익:
-
순이익/손실:
$-43.10M
주가수익비율:
-0.2013
EPS:
-6.2098
순현금흐름:
$-26.38M
1주 성능:
-1.57%
1개월 성능:
-31.69%
6개월 성능:
-14.68%
1년 성능:
-63.50%
1일 변동 폭
$1.24
$1.31
1주일 범위
$1.24
$1.31
52주 변동 폭
$1.20
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
명칭
Tempest Therapeutics Inc
전화
415-798-8589
주소
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
1.25 | 18.51M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-08 | 개시 | Jefferies | Buy |
Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스
Tempest Therapeutics (TPST) Edges Higher as Stock Tests Resistance Near $1.34EMA Signal - newsline.com
Director Richey William Drake reports 2,000 TPST shares on Form 3 - Stock Titan
Tempest Therapeutics (TPST) director awarded 25,000 stock options at $1.27 strike - Stock Titan
Warrant share approvals on ballot at Tempest Therapeutics (NASDAQ: TPST) - Stock Titan
Tempest Therapeutics Announces CFO Transition and Board Changes - TipRanks
Tempest Therapeutics appoints two directors to board - Investing.com UK
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com South Africa
Tempest Therapeutics (NASDAQ: TPST) CFO to depart while two independent directors join board - Stock Titan
Tempest Therapeutics, Inc. Announces Executive Changes, Effective June 5, 2026 - marketscreener.com
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - GlobeNewswire
Tempest Therapeutics Executes Warrant-Inducement Equity Financing Deal - The Globe and Mail
Tempest Therapeutics Raises $2.0M via Warrant Exercise, Issues New and Placement Agent Warrants - TradingView
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds - 富途牛牛
TEMPEST THERAPEUTICS INC WT EXP Company Profile & Introduction - Moomoo
Tempest Therapeutics (TPST) inks $2M warrant exercise and new warrant deal - Stock Titan
Tempest Therapeutics, Inc. Files 8-K SEC Report Detailing Company Information and Stock Listing on NASDAQ - Minichart
Tempest Therapeutics Announces Resignation of Board Director - TipRanks
Tempest Therapeutics (TPST) asks shareholders to approve warrants convertible into millions of shares - Stock Titan
Tempest Therapeutics (TPST) director Simantov resigns and waives unpaid fees - Stock Titan
TPST Q1 2026 Earnings: Significant EPS Miss and No Revenue Reflect Pre-Revenue Stage PressuresNegative Surprise Momentum - The Legal Advocate
Tempest Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Development StageEPS Surprise History - The Legal Advocate
Tempest Therapeutics secures $2M from warrant exercise By Investing.com - Investing.com Nigeria
Tempest Therapeutics secures $2M from warrant exercise - Investing.com
Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants - Quiver Quantitative
Tempest Therapeutics (TPST) Slumps 10%: Support Levels Under ScrutinyNegative Gamma - newsline.com
Tempest Therapeutics Inc. (TPST) Q1 2026 Earnings: Significant EPS Miss with No Revenue; Stock Edges UpInterim Report - Newser
Tempest Therapeutics announces resignation of three board members By Investing.com - Investing.com India
Tempest Therapeutics stock falls after $4.25 million direct offering - MSN
Tempest Therapeutics, Inc. Files Form 8-K with SEC – Company Information and Security Details (May 22, 2026) - Minichart
Tempest Therapeutics, Inc. 8-K Filing Details and Entity Information for May 19, 2026 - Minichart
Tempest Therapeutics (TPST) Edges Higher as Biotech Sector Shows Renewed InterestDiamond Pattern - Newser
Tempest Therapeutics announces resignation of three board members - Investing.com
Tempest Therapeutics Faces Nasdaq Listing and Governance Risks - TipRanks
Tempest Therapeutics Announces Multiple Board Director Resignations - TipRanks
Tempest Therapeutics receives Nasdaq notice for listing deficiencies - Investing.com UK
Tempest Therapeutics receives Nasdaq notice for listing deficiencies By Investing.com - Investing.com South Africa
Nasdaq flags Tempest Therapeutics (NASDAQ: TPST) on equity and board gaps - Stock Titan
[8-K] Tempest Therapeutics, Inc. Reports Material Event - Stock Titan
TPST Q1 2026 Earnings: Deep EPS Miss Highlights Clinical-Stage Biotech ChallengesNext Quarter Guidance - The Legal Advocate
TPST Q1 2026 Earnings: Deep EPS Miss Highlights Clinical-Stage ChallengesEPS Growth Rate - The Legal Advocate
Tempest Therapeutics (TPST) Stock: Jumps +3.65%, Approaching $1.93 2026-05-20Percent Below MA - Newser
Press Releases about Tempest Therapeutics, Inc.Common Stock - The Chronicle-Journal
Tempest Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Tempest Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tempest Therapeutics (NASDAQ: TPST) Q1 2026 loss widens on CAR-T deal charges and low cash - Stock Titan
Tempest Therapeutics reports Q1 2026 net loss of $27.7M, cash $1.8M - TradingView
Tempest Therapeutics Q1 net loss widens on asset acquisition costs - TradingView
Tempest Therapeutics (TPST) posts $27.7M loss, highlights 100% CAR‑T responses - Stock Titan
Tempest CAR-T trials log 100% response in 15 patients - Stock Titan
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Tempest Therapeutics Inc (TPST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):